HK Stock Market Move | FANGZHOU JIANKE (06086) rises over 6%; paid user repurchase rate reached 89.2% in the first half of the year; the company proactively deploys AI technology embedded in business processes.

FANGZHOU JIANKE (06086) rose over 6% intraday, up 5.42% as of press time, at HK$0.875. On the news front, in the first half of 2026, FANGZHOU JIANKE's revenue reached RMB 1.8245 billion (in RMB, same unit below), up 22.2% year-on-year; adjusted net profit reached RMB 18.708 million, up 6.4% year-on-year, maintaining a sound momentum of sustained profitability. As of the latest disclosure date, leveraging its broad and specialized registered physician resources, the company has built a medical service network covering multiple departments; its supply chain network covers more than 1,800 suppliers and over 1,000 pharmaceutical companies, with economies of scale gradually emerging. In the first half of 2026, FANGZHOU JIANKE's paid user repurchase rate reached as high as 89.2%. Most notably, amid rapid technological iteration, FANGZHOU JIANKE has proactively deployed AI technology embedded in business processes, developing an AI product matrix built on the Xingshi large model, which is expected to solve the cost challenge of scaled delivery of high-quality chronic disease services, transforming full-cycle services from small-scale project practices into a commercial business capable of reaching tens of millions of users.